Dr. Kiran Kumar Madallapalli

Kiran obtained his Bachelor’s Degree in Pharmacy from JNTU, Hyderabad, India and Master’s in Pharmaceutics from Biju Patnaik Technological University, Bhubaneshwar, India and Doctorate in Pharmaceutics from JNTUA, Anantapur. He has about 14 years of work experience.

He worked in the Generic Pharmaceutical industry for over 14 years, handling product and process development activities. During this time, he was responsible for developing several solid and liquid dosage form products and got several ANDAs approved by the US FDA, MHRA, Health Canada, TGA etc. After more than 10 years’ of experience in formulation development in Torrent, Zydus and Mylan, he moved to Hetero for setting up the Formulation R&D in Jadcherla. He set up the entire FR&D program from scratch and ran it for about 2 years in Hetero.

After successful establishment of FR&D in Hetero for about 2 years then moved to Appcure Labs Pvt ltd as AVP for Operations Head handling FR&D, AR&D, IPR, QA/RA, Pharmacokinetics during his tenure with Appcure. He managed and helped in setting up the R&D Centre, assembling a professional team and necessary infrastructure. He set up the entire R&D program from scratch and ran it for about 2 years in Appcure

He has rich experience that encompasses activities from formulation development to product approvals for the US, Europe and other regulated markets. He managed entire product development program from molecule selection, development strategy, risk assessment analysis, infringement analysis and regulatory filings of generic products. He has several patents more than 10, at various stages, to his credit. He was exposed to generic product development from Para I to Para IV filings and he has some experience in filing NDAs as well.

Kiran has hands on experience in developing formulations of Antidepressant, Anti-allergic, Antiviral, Anti-diabetic and Cardiovascular drugs. His research projects included development of Para IV / modified release / sustained release generic formulations based on matrix / pelletization / osmotic delivery technologies for oral solid dosage forms. He has several publications and research papers to his credit.

He joined Finoso Pharma in Feb 2015 and has been running the company successfully ever since as its Director.